Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade

Core Viewpoint - Theravance Biopharma (TBPH) shares have increased by 1.7% over the past four weeks, closing at $18.79, with a mean price target of $26.71 indicating a potential upside of 42.2% according to Wall Street analysts [1] Price Targets - The average price target consists of seven estimates ranging from a low of $13.00 to a high of $42.00, with a standard deviation of $11.1, indicating variability among analysts [2] - The lowest estimate suggests a decline of 30.8% from the current price, while the highest estimate indicates a potential upside of 123.5% [2] Analyst Sentiment - Analysts are optimistic about TBPH's earnings prospects, as indicated by a trend of upward revisions in earnings estimates, which historically correlates with stock price movements [4][11] - Over the past 30 days, one earnings estimate has increased, leading to a 6.7% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank - TBPH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of TBPH's potential gains, the implied direction of price movement appears to be a useful guide for investors [14]